论文部分内容阅读
目的研究诱骗受体3(DcR3)在人上皮性卵巢癌组织的表达及其临床意义。方法对2012年3月至2015年6月我院妇产科收治并手术治疗的66例上皮性卵巢癌组织及41例良性卵巢肿瘤组织的临床资料及组织病理学标本进行回顾性分析。用免疫组织化学SP法检测良性卵巢肿瘤组织及上皮性卵巢癌组织中DcR3蛋白的表达水平,用已知阳性组织切片作为阳性对照,以PBS溶液代替一抗作为阴性对照,分析其表达与患者临床病理学特征及生存时间的关系。结果在上皮性卵巢癌中,Ⅰ~Ⅱ与Ⅲ~Ⅳ期的DcR3阳性表达率分别为68.4%和89.4%,Ⅲ~Ⅳ期与Ⅰ~Ⅱ期比较差异有统计学意义(P<0.05);高、低2个分化组DcR3阳性表达率分别为66.7%和91.1%,低分化组与高分化组比较差异有统计学意义(P<0.05);淋巴结转移组的DcR3阳性表达率为91.3%,与无转移组的65.0%比较差异有统计学意义(P<0.05)。免疫组化染色显示,DcR3主要在细胞质和细胞膜中表达,DcR3在上皮性卵巢癌组织及良性卵巢肿瘤组织中的阳性表达率分别为83.3%,29.3%,癌组织与良性肿瘤组织比较差异有统计学意义(P<0.05)。DcR3阳性患者的中位生存时间为28.4个月,与阴性患者的50.2个月比较差异有统计学意义(HR=1.90,95%CI:1.09~3.66,P<0.05)。结论 DcR3蛋白可作为卵巢癌患者的预后不良的生物学标志物。
Objective To study the expression of decoy receptor 3 (DcR3) in human epithelial ovarian cancer and its clinical significance. Methods The clinical data and histopathological features of 66 cases of epithelial ovarian cancer and 41 cases of benign ovarian tumors treated in our department from March 2012 to June 2015 were retrospectively analyzed. Immunohistochemical SP method was used to detect the expression of DcR3 protein in benign ovarian tumor tissues and epithelial ovarian cancer tissues. The positive tissue sections were used as positive control, PBS solution instead of primary antibody was used as negative control, and the expression of DcR3 protein was analyzed. Pathological features and the relationship between survival time. Results The positive rates of DcR3 expression in stage Ⅰ ~ Ⅱ and stage Ⅲ ~ Ⅳ were 68.4% and 89.4% respectively in epithelial ovarian cancer. The difference between stage Ⅲ ~ Ⅳ and stage Ⅰ ~ Ⅱ was statistically significant (P <0.05). The positive rates of DcR3 in high and low differentiation groups were 66.7% and 91.1%, respectively. There was significant difference between poorly differentiated group and well differentiated group (P <0.05). The positive rate of DcR3 in lymph node metastasis group was 91.3% Compared with 65.0% in non-metastasis group, the difference was statistically significant (P <0.05). Immunohistochemical staining showed that DcR3 was mainly expressed in cytoplasm and cell membrane. The positive expression rates of DcR3 in epithelial ovarian cancer tissues and benign ovarian tumor tissues were 83.3% and 29.3%, respectively. The difference between cancer tissues and benign tumor tissues was statistically significant Significance (P <0.05). The median survival time was 28.4 months in DcR3-positive patients compared with 50.2 months in negative patients (HR = 1.90, 95% CI: 1.09-3.66, P <0.05). Conclusion DcR3 protein can be used as a poor prognostic biomarker for ovarian cancer patients.